Search results
Results from the WOW.Com Content Network
An experimental drug is a medicinal product (a drug or vaccine) that has not yet received approval from governmental regulatory authorities for routine use in human or veterinary medicine. A medicinal product may be approved for use in one disease or condition but still be considered experimental for other diseases or conditions.
Experimental drugs for Alzheimer's disease (1 C, 20 P) Experimental gene therapies (22 P) Experimental monoclonal antibodies (53 P) Experimental non-hallucinogens (11 P)
Shqip; Sicilianu; සිංහල ... Experimental drugs (15 C, 291 P) F. Fictional medicines and drugs (27 P) H. Hoaxes about drugs (1 C, 5 P) Human drug metabolites ...
Experimental cancer treatments are normally available only to people who participate in formal research programs, which are called clinical trials. Occasionally, a seriously ill person may be able to access an experimental drug through an expanded access program. Some of the treatments have regulatory approval for treating other conditions.
This category is for hallucinogens that are under development as experimental drugs for treatment of medical conditions. See also list of investigational hallucinogens and entactogens . Pages in category "Experimental hallucinogens"
Blarcamesine (developmental code name ANAVEX 2-73) is an experimental drug which is under development for the treatment of Alzheimer's disease and a variety of other indications. [1] Blarcamesine acts as an agonist of the sigma σ 1 receptor, the muscarinic acetylcholine M 1 receptor, and the ionotropic glutamate NMDA receptor. [2] [1]
This page was last edited on 3 December 2023, at 22:17 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Eplivanserin (SR-46,349; planned trade name Ciltyri) was an experimental drug for the treatment of insomnia which was being developed by Sanofi Aventis. [1]Sanofi Aventis announced in December 2009 that it was withdrawing its application for approval of eplivanserin from both the U.S. Food and Drug Administration and the European Medicines Agency.